The equivalence of different types of electric pulses for electrochemotherapy with cisplatin - an in vitro study
- PMID: 38378034
- PMCID: PMC10878774
- DOI: 10.2478/raon-2024-0005
The equivalence of different types of electric pulses for electrochemotherapy with cisplatin - an in vitro study
Abstract
Background: Electrochemotherapy (ECT) is a treatment involving the administration of chemotherapeutics drugs followed by the application of 8 square monopolar pulses of 100 μs duration at a repetition frequency of 1 Hz or 5000 Hz. However, there is increasing interest in using alternative types of pulses for ECT. The use of high-frequency short bipolar pulses has been shown to mitigate pain and muscle contractions. Conversely, the use of millisecond pulses is interesting when combining ECT with gene electrotransfer for the uptake of DNA-encoding proteins that stimulate the immune response with the aim of converting ECT from a local to systemic treatment. Therefore, the aim of this study was to investigate how alternative types of pulses affect the efficiency of the ECT.
Materials and methods: We performed in vitro experiments, exposing Chinese hamster ovary (CHO) cells to conventional ECT pulses, high-frequency bipolar pulses, and millisecond pulses in the presence of different concentrations of cisplatin. We determined cisplatin uptake by inductively coupled plasma mass spectrometry and cisplatin cytotoxicity by the clonogenic assay.
Results: We observed that the three tested types of pulses potentiate the uptake and cytotoxicity of cisplatin in an equivalent manner, provided that the electric field is properly adjusted for each pulse type. Furthermore, we quantified that the number of cisplatin molecules, resulting in the eradication of most cells, was 2-7 × 107 per cell.
Conclusions: High-frequency bipolar pulses and millisecond pulses can potentially be used in ECT to reduce pain and muscle contraction and increase the effect of the immune response in combination with gene electrotransfer, respectively.
Keywords: cisplatin uptake; electrochemotherapy; electroporation; equivalent pulse parameters; phenomenological model.
© 2024 Maria Scuderi et al., published by Sciendo.
Figures





Similar articles
-
The use of high-frequency short bipolar pulses in cisplatin electrochemotherapy in vitro.Radiol Oncol. 2019 Jun 1;53(2):194-205. doi: 10.2478/raon-2019-0025. Radiol Oncol. 2019. PMID: 31194692 Free PMC article.
-
Nanosecond electric pulses are equally effective in electrochemotherapy with cisplatin as microsecond pulses.Radiol Oncol. 2022 Aug 14;56(3):326-335. doi: 10.2478/raon-2022-0028. Radiol Oncol. 2022. PMID: 35962956 Free PMC article.
-
Electroporation with nanosecond pulses and bleomycin or cisplatin results in efficient cell kill and low metal release from electrodes.Bioelectrochemistry. 2021 Aug;140:107798. doi: 10.1016/j.bioelechem.2021.107798. Epub 2021 Mar 9. Bioelectrochemistry. 2021. PMID: 33743336
-
Microsecond and nanosecond electric pulses in cancer treatments.Bioelectromagnetics. 2012 Feb;33(2):106-23. doi: 10.1002/bem.20692. Epub 2011 Aug 3. Bioelectromagnetics. 2012. PMID: 21812011 Review.
-
Utility of electrochemotherapy in melanoma treatment.Curr Opin Oncol. 2012 Mar;24(2):155-61. doi: 10.1097/CCO.0b013e32834fcaa8. Curr Opin Oncol. 2012. PMID: 22249204 Review.
Cited by
-
Threshold Interphase Delay for Bipolar Pulses to Prevent Cancellation Phenomenon during Electrochemotherapy.Int J Mol Sci. 2024 Aug 12;25(16):8774. doi: 10.3390/ijms25168774. Int J Mol Sci. 2024. PMID: 39201461 Free PMC article.
-
Efficient gene transfer by pulse parameters for electrochemotherapy of cells in vitro and in muscle and melanoma tumors in mice.Radiol Oncol. 2025 Apr 21;59(2):203-212. doi: 10.2478/raon-2025-0027. eCollection 2025 Jun 1. Radiol Oncol. 2025. PMID: 40256892 Free PMC article.
References
-
- Campana LG, Miklavčič D, Bertino G, Marconato R, Valpione S, Imarisio I. et al. Electrochemotherapy of superficial tumors – current status: basic principles, operating procedures, shared indications, and emerging applications. Sem Oncol. 2019;46:173–91. doi: 10.1053/j.seminoncol.2019.04.002. - DOI - PubMed
MeSH terms
Substances
LinkOut - more resources
Full Text Sources